16 results on '"Bader FM"'
Search Results
2. Insights into cardiorenal interactions in acute decompensated heart failure.
- Author
-
Bader FM and Attallah N
- Subjects
- Acute Kidney Injury therapy, Cardio-Renal Syndrome diagnosis, Heart Failure physiopathology, Heart Failure therapy, Humans, Prognosis, Ultrafiltration, Acute Disease, Acute Kidney Injury etiology, Cardio-Renal Syndrome physiopathology, Heart Failure complications, Kidney physiopathology
- Abstract
Purpose of Review: Acute decompensated heart failure (ADHF) is one of the biggest challenges in the management of chronic heart failure. Despite the advances in medical and device therapy, high readmission and mortality rates continue to be a burden on healthcare systems worldwide. One of the strongest predictors of adverse outcomes in ADHF is renal dysfunction, referred to as cardiorenal syndrome (CRS) type 1. This review discusses some of the recently introduced findings related to the pathophysiology, diagnosis, and management of this disorder., Recent Findings: There is a better understanding of the pathophysiology of ADHF and CRS. Systemic and intrarenal hemodynamic data provided a much deeper insight into various mechanisms of interaction between the heart and the kidney. Novel biomarkers have been discovered and developed recently to help diagnose and predict prognosis of CRS. Although there was optimism toward using ultrafiltration in treating ADHF with CRS, recent data did not support that, and management remains primarily driven by reversing ADHF hemodynamic and neurohormonal derangements., Summary: ADHF with CRS carries poor prognosis and high mortality. There is a need for individual risk assessment and management. A dedicated experienced multidisciplinary team is needed to diagnose and manage patients with this problem. Different approaches are needed to address the complex elements of this disorder.
- Published
- 2017
- Full Text
- View/download PDF
3. Immune function surveillance: association with rejection, infection and cardiac allograft vasculopathy.
- Author
-
Heikal NM, Bader FM, Martins TB, Pavlov IY, Wilson AR, Barakat M, Stehlik J, Kfoury AG, Gilbert EM, Delgado JC, and Hill HR
- Subjects
- Adolescent, Adult, Aged, Angiography methods, Biopsy, Coronary Artery Disease therapy, Cytokines metabolism, Female, Heart physiology, Humans, Immunosuppression Therapy methods, Interleukin-5 metabolism, Ki-1 Antigen metabolism, Male, Middle Aged, Prospective Studies, ROC Curve, Young Adult, Graft Rejection immunology, Heart Transplantation methods, Immune System, Myocardium pathology
- Abstract
Background: Rejection, cardiac allograft vasculopathy (CAV), and infection are significant causes of mortality in heart transplantation recipients. Assessing the immune status of a particular patient remains challenging. Although endomyocardial biopsy (EMB) and angiography are effective for the identification of rejection and CAV, respectively, these are expensive, invasive, and may have numerous complications. The aim of this study was to evaluate the immune function and assess its utility in predicting rejection, CAV, and infection in heart transplantation recipients., Methods: We prospectively obtained samples at the time of routine EMB and when clinically indicated for measurement of the ImmuKnow assay (IM), 12 cytokines and soluble CD30 (sCD30). EMB specimens were evaluated for acute cellular rejection, and antibody-mediated rejection (AMR). CAV was diagnosed by the development of angiographic coronary artery disease. Infectious episodes occurring during the next 30 days after testing were identified by the presence of positive bacterial or fungal cultures and/or viremia that prompted treatment with antimicrobials., Results: We collected 162 samples from 56 cardiac transplant recipients. There were 31 infection episodes, 7 AMR, and 4 CAV cases. The average IM value was significantly lower during infection, (P = .04). Soluble CD30 concentrations showed significantly positive correlation with infection episodes, (P = .001). Significant positive correlation was observed between interleukin-5(IL-5) and AMR episodes (P = .008). Tumor necrosis factor-α and IL-8 showed significant positive correlation with CAV (P = .001)., Conclusions: Immune function monitoring appears promising in predicting rejection, CAV, and infection in cardiac transplantation recipients. This approach may help in more individualized immunosuppression and it may also minimize unnecessary EMBs and cardiac angiographies., (Published by Elsevier Inc.)
- Published
- 2013
- Full Text
- View/download PDF
4. A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation.
- Author
-
Kfoury AG, Snow GL, Budge D, Alharethi RA, Stehlik J, Everitt MD, Miller DV, Drakos SG, Reid BB, Revelo MP, Gilbert EM, Selzman CH, Bader FM, Connelly JJ, and Hammond ME
- Subjects
- Adolescent, Adult, Aged, Biopsy, Child, Child, Preschool, Female, Follow-Up Studies, Graft Rejection epidemiology, Graft Rejection pathology, Humans, Infant, Infant, Newborn, Male, Middle Aged, Myocardium immunology, Myocardium pathology, Prognosis, Retrospective Studies, Severity of Illness Index, Young Adult, Antibodies immunology, Graft Rejection immunology, Heart Transplantation
- Abstract
Background: Growing evidence suggests worse cardiac allograft vasculopathy and mortality in patients with asymptomatic antibody-mediated rejection (AMR). Debate continues about whether therapeutic intervention is warranted to avoid adverse outcomes. In this study we examine the course of individual episodes of untreated asymptomatic AMR on follow-up endomyocardial biopsy (EMB)., Methods: The U.T.A.H. Cardiac Transplant Program database was queried for transplant recipients between 1985 and 2009 who survived beyond 1 year and had at least 1 episode of lone AMR with a follow-up EMB. All EMBs were screened for AMR by immunofluorescence and graded for severity. Data were analyzed based on time from transplant (early, ≤12 months; late, >12 months)., Results: Nine hundred fifty-eight patients with a total of 15,448 biopsies qualified for the study. Average age at transplant was 46.7 years; 13% of the patients were female. Within the first year post-transplant, asymptomatic AMR was diagnosed in 13.6% of biopsies compared with 5.2% beyond 1 year. AMR resolved in 65% (early) vs 75% (late) on follow-up EMB. More severe AMR was less likely to improve regardless of time from transplant. Furthermore, after an episode of AMR had resolved, the recurrence rate at 3, 6 and 12 months was 44%, 50.1% and 56.2%, respectively., Conclusions: The incidence of AMR is higher in the first year post-transplant and the likelihood of resolution is less on follow-up EMB, especially when more severe. A small but significant number of cases became worse or did not change. These new findings may be helpful in planning future studies that test whether therapeutic interventions on asymptomatic AMR favorably impact outcomes., (Copyright © 2012 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
5. Noninvasive diagnosis of cardiac allograft rejection using echocardiography indices of systolic and diastolic function.
- Author
-
Bader FM, Islam N, Mehta NA, Worthen N, Ishihara S, Stehlik J, Gilbert EM, and Litwin SE
- Subjects
- Biopsy, Diastole, Graft Rejection diagnostic imaging, Graft Rejection etiology, Graft Rejection pathology, Graft Rejection physiopathology, Humans, Mitral Valve diagnostic imaging, Mitral Valve physiopathology, Myocardium pathology, Predictive Value of Tests, Prospective Studies, Regression Analysis, Systole, Transplantation, Homologous, Treatment Outcome, Utah, Echocardiography, Doppler, Graft Rejection diagnosis, Heart Transplantation adverse effects, Ventricular Function, Left
- Abstract
Background: Limited and conflicting data exist on the diagnosis of cardiac allograft rejection with the use of echocardiography. The purpose of our study was to evaluate various systolic and diastolic indices, including newer tissue Doppler imaging techniques, in diagnosing cardiac allograft rejection., Methods: We prospectively performed 426 echocardiography studies at the time of endomyocardial biopsy in 54 cardiac transplant patients. We measured left ventricular (LV) systolic and diastolic dimensions, mitral inflow pattern and annular velocities, and the myocardial performance index. Biopsies were assessed for cellular rejection and antibody-mediated rejection (AMR)., Results: Mild cellular rejection was diagnosed in 74 biopsy specimens and significant cellular rejection in 10 biopsy specimens. AMR was diagnosed in 30 biopsy specimens. In patients with mild or significant cellular rejection, no significant differences in echocardiographic parameters were observed. In patients with AMR, LV fractional shortening was significantly reduced compared with those with no AMR (mean±SD 31.8±8.9% vs 36.0±7.1%; P=.02)., Conclusions: Although 1 echocardiographic parameter was statistically different in the setting of rejection, lack of consistency and overlap between nonrejection and rejection groups does not permit definitive noninvasive diagnosis of cardiac allograft rejection using this imaging modality., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
6. Allograft rejection in patients supported with continuous-flow left ventricular assist devices.
- Author
-
Healy AH, Mason NO, Hammond ME, Reid BB, Clayson SE, Drakos SG, Kfoury AG, Patel AN, Bull DA, Budge D, Alharethi RA, Bader FM, Gilbert EM, Stehlik J, and Selzman CH
- Subjects
- Female, Humans, Male, Middle Aged, Prosthesis Design, Retrospective Studies, Graft Rejection epidemiology, Heart Transplantation, Heart-Assist Devices
- Abstract
Background: Both pulsatile-flow and continuous-flow left ventricular assist devices (LVADs) successfully provide patients a bridge to transplantation. Some data suggest that continuous-flow pumps increase the risk of allograft rejection, contributing to posttransplantation morbidity and mortality. We sought to analyze the relationship between LVAD flow characteristics and subsequent allograft rejection in bridge to transplant (BTT) patients., Methods: Patients with LVADs from the UTAH Transplant Affiliated Hospitals were retrospectively analyzed. Rejection was determined pathologically according to the International Society for Heart and Lung Transplantation revised cardiac allograft rejection scale. Multimodal statistical analyses were applied., Results: Of 1,076 patients who underwent transplantation over a 26-year period, 151 had LVADs. Of these, 111 (77 pulsatile flow, 34 continuous flow) patients had pathologic data available. There was no difference in overall rejection (grades 1R to 3R) between the pulsatile-flow LVAD and continuous-flow LVAD groups (2.00 ± 1.43 versus 1.50 ± 1.16 episodes/year; p = 0.076.) Patients with pulsatile-flow LVADs had more clinically relevant (grades 2R to 3R) rejection than did patients with continuous-flow LVADs (0.49 ± 0.72 versus 0.12 ± 0.33 episodes/year; p < 0.001). There was no survival difference at 1 year (p = 0.920) or 4 years (p = 0.721) after transplantation., Conclusions: Patients with continuous-flow LVADs have similar overall rejection rates and a reduced rate of clinically relevant rejection compared with patients with pulsatile-flow LVADs during the first year after transplantation. Although there is theoretical concern that nonphysiologic, nonpulsatile flow could alter the neurohormonal profile of patients in heart failure, we are encouraged that the type of LVAD circulation does not influence posttransplantation allograft survival., (Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
7. Antibody testing for cardiac antibody-mediated rejection: which panel correlates best with cardiovascular death?
- Author
-
Revelo MP, Stehlik J, Miller D, Snow GL, Everitt MD, Budge D, Bader FM, Alharethi RA, Gilbert EM, Reid BB, Selzman CH, Hammond ME, and Kfoury AG
- Subjects
- Adolescent, Adult, Aged, Antibodies immunology, Biomarkers blood, Biopsy, Complement C3d metabolism, Complement C4b, Female, Fibrin metabolism, Graft Rejection epidemiology, HLA-DR Antigens blood, Heart Transplantation pathology, Humans, Infant, Infant, Newborn, Male, Middle Aged, Myocardium pathology, Peptide Fragments blood, Prognosis, Proportional Hazards Models, Retrospective Studies, Risk Factors, Survival Rate, Young Adult, Antibodies blood, Graft Rejection diagnosis, Graft Rejection immunology, Heart Transplantation immunology, Heart Transplantation mortality
- Abstract
Background: Recent efforts are being undertaken to update and refine current diagnostic criteria for antibody-mediated rejection (AMR) in heart transplantation. We believe that the appropriate reactants are those that best predict the adverse consequences of AMR and therefore tested various models using different reactants to find the best predictors of cardiovascular mortality in pathologically defined AMR., Methods: The study group included only patients in whom all immunofluorescence antibodies of interest had been tested on biopsy specimens obtained after 2002 when C4d was routinely added. We analyzed our data using 3 Cox proportional hazard models with time-varying covariates using an end point of cardiovascular mortality, as previously defined., Results: In 3,712 biopsy specimens from 422 patients, the 2-antibody model achieved a value of R(2) = 0.930 using C3d and C4d antibodies alone. A model that used 4 antibodies--C3d, C4d, human leukocyte antigen-D related (HLA-DR) and fibrin--was superior (R(2) = 0.988). The model that best predicted cardiovascular mortality included all 6 antibodies: HLA-DR, immunoglobulin (Ig) G, IgM, C3d, C4d, and fibrin (R(2) = 0.989). The models using 4 or 6 antibodies were significantly superior to the model using only C3d and C4d (for each interaction, p < 0.0001)., Conclusions: The combination of complement components, HLA-DR and fibrin, is valuable in defining AMR in patients at risk for allograft loss from cardiovascular causes. Fibrin is particularly important for detecting the presence of severe AMR, with a high likelihood of poor long-term patient outcome., (Copyright © 2011 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
8. Can echocardiographic evaluation of cardiopulmonary hemodynamics decrease right heart catheterizations in end-stage heart failure patients awaiting transplantation?
- Author
-
Kuppahally SS, Michaels AD, Tandar A, Gilbert EM, Litwin SE, and Bader FM
- Subjects
- Cardiac Catheterization methods, Female, Follow-Up Studies, Heart Failure physiopathology, Heart Failure surgery, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Vascular Resistance physiology, Cardiac Catheterization statistics & numerical data, Echocardiography methods, Heart Failure diagnostic imaging, Heart Transplantation, Pulmonary Wedge Pressure physiology, Ventricular Function, Right physiology, Waiting Lists
- Abstract
Candidacy for heart transplantation is influenced by the severity of pulmonary hypertension. In this study, invasive hemodynamics from right-sided cardiac catheterization were compared with values obtained by validated equations from Doppler 2-dimensional transthoracic echocardiography. This prospective study was conducted in 40 patients with end-stage heart failure evaluated for heart transplantation or ventricular assist device implantation. Transthoracic echocardiography and right-sided cardiac catheterization were performed within 4 hours. From continuous-wave Doppler of the tricuspid regurgitation jet, pulmonary artery systolic pressure was calculated as the peak gradient across the tricuspid valve plus right atrial pressure estimated from inferior vena cava filling. Mean pulmonary artery pressure was calculated as (0.61 × pulmonary artery systolic pressure) + 2. Pulmonary vascular resistance (PVR) was calculated as (tricuspid regurgitation velocity/right ventricular outflow tract time-velocity integral × 10) + 0.16. Pulmonary capillary wedge pressure was calculated as 1.91 + (1.24 × E/E'). Pearson's correlation and Bland-Altman analysis of mean differences between echocardiographic and right-sided cardiac catheterization measurements were statistically significant for all hemodynamic parameters (pulmonary artery systolic pressure: r = 0.82, p < 0.05, mean difference 3.1 mm Hg, 95% confidence interval [CI] -0.2 to 6.3; mean pulmonary artery pressure: r = 0.80, p < 0.05, mean difference 2.5 mm Hg, 95% CI 0.3 to 4.6; PVR: r = 0.52, p < 0.05, mean difference 0.8 Wood units, 95% CI 0.3 to 1.4; pulmonary capillary wedge pressure: r = 0.65, p < 0.05, mean difference 2.2 mm Hg, 95% CI 0.1 to 4.3). Compared with right-sided cardiac catheterization, PVR by Doppler echocardiography identified all patients with PVR > 4 Wood units (n = 4), 73% of patients with PVR <2 Wood units (n = 8), and 52% of patients with PVR from 2 to 4 Wood units (n = 10). In conclusion, echocardiographic estimation of cardiopulmonary hemodynamics is reliable in patients with end-stage cardiomyopathy. The noninvasive assessment of hemodynamics by echocardiography may be able to decrease the number of serial right-sided cardiac catheterizations in selected patients awaiting heart transplantation. However, in patients with borderline PVR, right-sided cardiac catheterization is indicated to assess eligibility for transplantation., (Copyright © 2010 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
9. Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure.
- Author
-
Bader FM, Gilbert EM, Mehta NA, and Bristow MR
- Subjects
- Adult, Aged, Aged, 80 and over, Chronic Disease, Coronary Circulation, Cyclic AMP-Dependent Protein Kinases, Cyclic GMP-Dependent Protein Kinases, Disease Progression, Double-Blind Method, Electrocardiography, Ambulatory, Female, Health Status Indicators, Hemodynamics, Humans, Linear Models, Male, Middle Aged, Pulmonary Wedge Pressure, Statistics as Topic, Stroke Volume, Ventricular Function, Left, Cardiotonic Agents therapeutic use, Dobutamine therapeutic use, Enoximone therapeutic use, Sympathomimetics therapeutic use
- Abstract
Few data exist on the safety of transferring patients to standard oral therapy for chronic heart failure (CHF) after acute management with inotropic agents. This study compares hemodynamic responses and cardiac dysrhythmic effects of continuous infusion of enoximone, dobutamine, or placebo in patients with moderate to severe CHF. The authors enrolled 136 patients who were randomly assigned to either open-label dobutamine or double-blind enoximone vs placebo. After 24 hours of treatment, the study was unblinded. Patients receiving placebo completed the study. Patients receiving enoximone or dobutamine received the infusion for an additional 24 hours and were then switched to standard oral therapy for 72 hours. Compared with placebo, both enoximone and dobutamine increased cardiac index and decreased pulmonary capillary wedge pressure (PCWP). Compared with dobutamine, enoximone significantly increased cardiac index after the first 24 hours of infusion and significantly decreased PCWP throughout the infusion period. There was no difference in the incidence of arrhythmias between enoximone and dobutamine. More patients (65%) tolerated the switch to oral therapy in the enoximone group compared with dobutamine (49%; P =.12). Enoximone is effective in improving the hemodynamics in patients with moderate to severe CHF and is tolerated at least as well as dobutamine., (© 2010 Wiley Periodicals, Inc.)
- Published
- 2010
- Full Text
- View/download PDF
10. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection.
- Author
-
Kfoury AG, Hammond ME, Snow GL, Drakos SG, Stehlik J, Fisher PW, Reid BB, Everitt MD, Bader FM, and Renlund DG
- Subjects
- Adult, Antibodies immunology, Cardiovascular Diseases immunology, Female, Graft Rejection pathology, Humans, Immunity, Cellular immunology, Male, Middle Aged, Survival Analysis, Cardiovascular Diseases mortality, Graft Rejection immunology, Heart Transplantation immunology, Heart Transplantation mortality
- Abstract
Background: Little has been reported on the clinical significance of asymptomatic antibody-mediated rejection (AMR) alone or mixed rejection (MR), defined as concurrent cellular rejection (CR) and AMR in heart transplantation. In this study, we examined whether a differential impact on cardiovascular mortality (CVM) existed when comparing asymptomatic AMR, to stable MR or CR., Methods: The Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program pathology database of all heart transplant recipients between 1985 and 2004 was queried. Patients were classified as cellular, antibody-mediated, or mixed rejectors based on their predominant pattern of rejection type in the first three months post-transplant. Kaplan-Meier survival curves were fit to each of the three groups and analyses were adjusted for age at the time of transplant, gender, and underlying primary cardiac disease., Results: Eight hundred and sixty nine heart transplant recipients qualified for analysis. Over the study period, patients with asymptomatic AMR or stable MR patterns had significantly worse CVM when compared to patients with stable CR pattern (AMR, 21.2%; MR, 18.0%; CR, 12.6%; AMR vs. CR, p = 0.009; MR vs. CR, p = 0.001). In contrast, CVM was comparable in patients with asymptomatic AMR or stable MR patterns (p = 0.9)., Conclusions: Asymptomatic or subclinical AMR and MR are clinically relevant, should be recognized, and deserve consideration for therapeutic intervention in hopes of avoiding adverse outcomes.
- Published
- 2009
- Full Text
- View/download PDF
11. Time-dependent changes in B-type natriuretic peptide after heart transplantation: correlation with allograft rejection and function.
- Author
-
Bader FM, Rogers RK, Kfoury AG, Gilbert EM, Horne BD, Stehlik J, and Renlund DG
- Subjects
- Biomarkers, Biopsy, Creatinine blood, Endocardium pathology, Female, Follow-Up Studies, Graft Rejection pathology, Heart Transplantation pathology, Hemodynamics physiology, Humans, Male, Myocardium pathology, Predictive Value of Tests, Statistics as Topic, Stroke Volume physiology, Time Factors, Ventricular Function, Left physiology, Graft Rejection blood, Heart Transplantation physiology, Natriuretic Peptide, Brain blood
- Abstract
Endomyocardial biopsy is the gold standard to diagnose cardiac allograft rejection, although a noninvasive modality such as brain natriuretic peptide (BNP) is attractive. The authors examined the correlation of BNP levels with rejection patterns and allograft function in cardiac allograft recipients followed up to 8 years. One hundred forty-four consecutive patients underwent endomyocardial biopsy, right heart catheterization, and blood sampling. BNP levels decreased during the first 6 months after transplant but then reached a plateau. Time-dependent correlations were made between BNP levels and allograft rejection, left ventricular ejection fraction, pulmonary capillary wedge pressure, right atrial pressure, and serum creatinine. BNP levels were not different between patients with any rejection pattern and no rejection prior to or after 6 months following transplant. BNP levels did not correlate with ejection fraction, pulmonary capillary wedge pressure, right atrial pressure, or creatinine in the first 6 months after transplant. Statistically significant correlations existed between BNP and these parameters after 6 months following transplant. In cardiac transplant recipients, BNP levels decrease in the first 6 months following transplant and then reach a plateau regardless of the presence, type, or severity of allograft rejection. BNP levels do predict allograft rejection but correlate with allograft function after 6 months following transplant.
- Published
- 2009
- Full Text
- View/download PDF
12. A clinical correlation study of severity of antibody-mediated rejection and cardiovascular mortality in heart transplantation.
- Author
-
Kfoury AG, Renlund DG, Snow GL, Stehlik J, Folsom JW, Fisher PW, Reid BB, Clayson SE, Gilbert EM, Everitt MD, Bader FM, Singhal AK, and Hammond ME
- Subjects
- Adult, Biopsy, Cardiovascular Diseases physiopathology, Female, Graft Rejection mortality, Heart Transplantation pathology, Humans, Isoantibodies blood, Male, Middle Aged, Proportional Hazards Models, Regression Analysis, Retrospective Studies, Severity of Illness Index, Survival Rate, Utah epidemiology, Cardiovascular Diseases mortality, Graft Rejection physiopathology, Heart Transplantation immunology, Heart Transplantation mortality
- Abstract
Background: The current International Society for Heart and Lung Transplantation (ISHLT) diagnostic criteria for antibody-mediated rejection (AMR) designate AMR as either absent (AMR 0) or present (AMR 1), without grading its severity. Yet, the extent of histologic and immunofluorescence (IF) findings of AMR varies across endomyocardial biopsies (EMBs). In this study, we hypothesized that the severity of AMR, as assessed on EMBs, correlates with cardiovascular mortality in heart transplant recipients., Methods: All EMBs from 1985 to 2005 were evaluated. Biopsy specimens were uniformly studied by light microscopy and IF early post-transplant. A comprehensive vascular score (V1: no AMR, to V5: severe AMR) was prospectively assigned to each EMB, based on severity of both histologic and IF findings. Univariate Cox proportional hazards regressions were performed using indicators of vascular scores alone, combined, and cumulatively., Results: Nine hundred six patients were transplanted and included in the study. Mean age was 46.6 +/- 15.5 years and 82% were male. A total of 26,236 EMBs comprised the study data. As expected, histologic and immunopathologic findings of AMR varied in severity. An incremental risk of cardiovascular mortality was found with more severe AMR whether vascular scores were analyzed individually (p = 0.001), in combination (p = 0.01) or cumulatively (p = 0.006)., Conclusions: The severity of AMR on EMBs correlates with an incremental cardiovascular mortality risk after heart transplantation, suggesting that AMR should be viewed as a spectrum rather than just as present or absent. Supplementing the ISHLT AMR diagnostic guidelines with a consensus severity scale is warranted.
- Published
- 2009
- Full Text
- View/download PDF
13. Early screening for antibody-mediated rejection in heart transplant recipients.
- Author
-
Kfoury AG, Hammond ME, Snow GL, Stehlik J, Reid BB, Long JW, Gilbert EM, Bader FM, Bull DA, and Renlund DG
- Subjects
- Adult, Algorithms, Biopsy, Complement System Proteins immunology, Female, Heart Transplantation adverse effects, Humans, Immunoglobulins immunology, Immunosuppression Therapy methods, Immunosuppressive Agents therapeutic use, Male, Middle Aged, Muromonab-CD3 therapeutic use, Myocardium immunology, Myocardium pathology, Retrospective Studies, Antibodies immunology, Graft Rejection diagnosis, Graft Rejection immunology, Heart Transplantation immunology, Mass Screening methods
- Abstract
Background: The International Society for Heart and Lung Transplantation (ISHLT) recently established a diagnostic scheme for antibody-mediated rejection (AMR). Currently, however, confirmatory immunohistochemistry studies are recommended only if AMR is clinically or histologically suspected. In this study, we examine whether a pattern of repetitive AMR occurred early enough after transplantation to warrant prospective immunohistochemistry screening in all recently transplanted recipients., Methods: We queried our pathology database of adult and pediatric endomyocardial biopsies (EMBs) from 1985 to 2005. All EMB specimens were prospectively studied by immunofluorescence in the early post-operative period. AMR was defined as the presence of complement and immunoglobulin deposits on frozen section. Only patients classified as antibody-mediated rejectors (>or=3 episodes of AMR) were included. Cumulative incidence and time from transplant to first and third AMR episodes were obtained., Results: Three hundred seventy-five of 870 heart transplant recipients had >or=3 episodes of AMR. Mean age of recipients was 45.6 years and 78% were male. A total of 19,569 EMBs comprised the study data. By 100 days post-transplant, 85% of patients had their first and 54% their third AMR. In addition, patients showed a clear trend of early clustering of AMR-positive biopsies. Results were similar regardless of whether or not muromonab-CD3 (Orthoclone OKT3) induction was used., Conclusions: We advocate early immunohistochemical surveillance testing for AMR to supplement the diagnostic algorithm established by the ISHLT, because a pattern of AMR becomes manifest soon after transplantation. This change will allow earlier detection of asymptomatic AMR and may prompt changes in immunosuppression strategies to avoid adverse outcomes.
- Published
- 2007
- Full Text
- View/download PDF
14. Percutaneous coronary interventions with stents in cardiac transplant recipients.
- Author
-
Bader FM, Kfoury AG, Gilbert EM, Barry WH, Humayun N, Hagan ME, Thomas H, and Renlund D
- Subjects
- Coronary Restenosis prevention & control, Cytomegalovirus Infections immunology, Female, Follow-Up Studies, Humans, Male, Reoperation, Retrospective Studies, Sirolimus therapeutic use, Angioplasty, Balloon, Coronary, Coronary Artery Disease therapy, Heart Transplantation, Stents
- Abstract
Background: Allograft coronary vasculopathy is a major cause of death beyond the first year after cardiac transplantation. The aim of this study was to review our experience with percutaneous coronary intervention (PCI) with stents in cardiac transplant recipients., Methods: We identified patients who were treated with PCI using stents. Patient characteristics, procedure information and clinical outcomes were assessed for these patients by review of their medical records. We also compared results for those who had bare metal stents vs those who had drug-eluting stents., Results: Forty patients from our program's 865 cardiac transplant recipients received a total of 78 coronary stents. There were 35 males (87.5%) and 5 females (12.5%). The indication for PCI was progressive asymptomatic coronary vasculopathy in 18 patients (45%), angina in 5 (12.5%), acute myocardial infarction (MI) in 4 (10%) and congestive heart failure (CHF) in 6 (15%). Primary success (<50% residual stenosis) was obtained in 71 (91%) of 78 stents. During the mean follow-up of 40.8 +/- 34.5 months, 6 patients died (15%) and 2 (5%) were re-transplanted. There was a lower rate of re-stenosis with drug-eluting stents (2 of 13, 15%) compared with bare metal stents (20 of 65, 31%), although this difference was not statistically significant (p = 0.27)., Conclusions: In cardiac transplant recipients, PCI with stents can be performed with high rates of primary success. Restenosis rates are higher compared with PCI in native coronary arteries. A trend toward less restenosis with drug-eluting stents was observed, which needs to be confirmed in larger studies.
- Published
- 2006
- Full Text
- View/download PDF
15. The effect of beta-blocker use on cyclosporine level in cardiac transplant recipients.
- Author
-
Bader FM, Hagan ME, Crompton JA, and Gilbert EM
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1 drug effects, ATP Binding Cassette Transporter, Subfamily B, Member 1 physiology, Absorption, Adrenergic beta-Antagonists therapeutic use, Carbazoles therapeutic use, Carvedilol, Drug Interactions, Humans, Hypertension drug therapy, Metoprolol therapeutic use, Propanolamines therapeutic use, Retrospective Studies, Adrenergic beta-Antagonists pharmacology, Carbazoles pharmacology, Cyclosporine pharmacokinetics, Heart Transplantation, Immunosuppressive Agents pharmacokinetics, Metoprolol pharmacology, Propanolamines pharmacology
- Abstract
Background: Beta-blockers are frequently used after cardiac transplantation for blood pressure control. There is no well-known interaction between beta-blockers and cyclosporine A (CsA). However, recent reports have suggested that carvedilol, but not metoprolol, modulates P-glycoprotein (P-gp), a membrane protein that regulates CsA absorption. We evaluated the effects of carvedilol and metoprolol on CsA level when initiated in cardiac transplant recipients., Methods: Using our cardiac transplant database, we identified patients who were started on either carvedilol or metoprolol for blood pressure control. We then compared their CsA doses and levels before and within 2 weeks after the initiation of beta-blocker therapy., Results: We found 20 patients taking metoprolol and 12 patients taking carvedilol. With initiation of metoprolol, CsA level decreased in 12 patients and increased in 8 patients. The mean CsA level before and after metoprolol initiation was 236 ng/ml and 253 ng/ml, respectively (p = 0.50). In an attempt to maintain a therapeutic CsA level, the mean CsA dose was not significantly adjusted (from a mean of 293 mg/day to a mean of 294 mg/day; p = 0.92). In the Carvedilol Group, CsA level increased in 10 of 12 patients. The mean CsA level before the initiation of carvedilol was 257 ng/ml. The mean CsA level after carvedilol initiation was 380 ng/ml (p = 0.009). In an attempt to maintain a therapeutic CsA level, the mean CsA dose was reduced by 10%, from a mean of 319 mg/day to a mean of 288 mg/day (p = 0.004)., Conclusion: Carvedilol, but not metoprolol, was associated with a significant increase in CsA levels after initiation in cardiac transplant recipients. Although carvedilol and CsA do not interact at the level of cytochrome P450 system, it appears that carvedilol influences CsA levels through its effects on P-gp. An average reduction of 10% is necessary on the CsA dose upon initiation of carvedilol, and close follow-up of the level is essential.
- Published
- 2005
- Full Text
- View/download PDF
16. Initiation and use of beta-blockers in class IV heart failure.
- Author
-
Bader FM, MacGregor JF, and Gilbert EM
- Subjects
- Female, Heart Failure classification, Heart Failure etiology, Hemodynamics drug effects, Humans, Male, Middle Aged, Phosphodiesterase Inhibitors therapeutic use, Prospective Studies, Randomized Controlled Trials as Topic, Ventricular Dysfunction, Left complications, Adrenergic beta-Antagonists therapeutic use, Heart Failure drug therapy
- Abstract
Treatment of patients with heart failure caused by left ventricular systolic dysfunction using b-adrenergic receptor antagonists (or b-blockers) results in improvements in symptoms, hemodynamics, left ventricular remodeling, morbidity, and mortality. Most patients studied in prospective, randomized placebo-controlled trials have had New York Heart Association (NYHA) functional class II or III symptoms. The efficacy of b-blockers in treating NYHA class IV patients is not as well-established. This review summarizes the published experience regarding the use of b-blockers in patients with advanced heart failure. Although treatment requires considerable care, the data support attempts at initiation of b-blockers in this group of patients.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.